Telix Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030
Updated on 04/25/2024
Telix Pharmaceuticals Stock Forecast and Price Target
The average price target of $14.50 for Telix Pharmaceuticals's stock set by two distinguished analysts in recent weeks would represent a potential downside of approximately -2.55% from the last closing price in April, 2024 if reached by the end of the year. This potential increase is based on a high estimate of $19.30 and a low estimate of $13.52. Even if you're not interested in TLX stock, you may be interested in its competitors.
-2.55% Downside
Telix Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Telix Pharmaceuticals's Price has grown, increasing from $0.00 to $0.00 – an increase of 100.00%. For next year, the 4 analysts predict Fair Value of $15.83, which would mean an increase of 100.00%. Over the next seven years, the pros' prediction is Fair Valueof $27.08, which would mean a seven-year growth forecast of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF89.12 | Buy/Sell | CHF105.00 | 20.68% |
| 7733 Stock Forecast | Olympus | Outperform |
18
|
¥2.23k | Buy/Sell | ¥2.30k | 7.74% |
| LNTH Stock Forecast | Lantheus Holdings | Buy |
14
|
$65.21 | Buy/Sell | $91.75 | 50.28% |
| SSKN Stock Forecast | STRATA Skin Sciences | Buy |
0
|
$0.56 | Buy/Sell | $3.60 | 310.71% |
| GTHP Stock Forecast | Guided Therapeutics | - |
0
|
$0.14 | Buy/Sell | $0.09B | -100.00% |
Telix Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Telix Pharmaceuticals's Revenue has grown, increasing from $5.21M to $502.55M – an increase of 9545.87%. In the following year, 0 experts forecast that Telix Pharmaceuticals's Revenue will decrease by 64.95%, to $176.16M. In 2030, professionals predict that Telix Pharmaceuticals's Revenue will decrease by 44.97%, to $276.54M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SCIE Stock Forecast | SpectraScience | - |
0
|
$0.00 | Buy/Sell | $0.15 | 0.00% |
| LCDX Stock Forecast | Caliber Imaging & Diagnostics | - |
0
|
$0.00 | Buy/Sell | $0.00 | 0.00% |
| VRSE.F Stock Forecast | Verisante Technology | - |
0
|
0.01 | Buy/Sell | 0.00 | -100.00% |
.jpg)
Telix Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Telix Pharmaceuticals's EBITDA has grown by 227.21%, from $-44.94M to $57.17M. For the next year, analysts are expecting EBITDA to reach $100.72M – an increase of 76.18%. Over the next seven years, experts predict that EBITDA will grow by 463.58%.
Telix Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Telix Pharmaceuticals's EBIT has grown from $-49.25M to $51.89M – a 205.36% increase. Next year, analysts are expecting EBIT to reach $84.89M – an increase of 63.60%. Over the next seven years, the forecast is for EBIT to grow by 515.73%.
Telix Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Telix Pharmaceuticals's EPS has grown, increasing from $-0.17 to $0.00 – an increase of 100.00%. For next year, the 4 analysts predict EPS of $0.19, which would mean an increase of 100.00%. Over the next seven years, the pros' prediction is EPSof $0.29, which would mean a seven-year growth forecast of 100.00%.
Site Navigation
.jpg)